Skip to main content

Global Liquid Biopsy Market is Projected to Reach $12,933 Million by 2030

 According to a new market intelligence report by BIS Research titled ‘Global Liquid Biopsy Market – Analysis and Forecast, 2020-2030’, The liquid biopsy market is projected to reach $12,933 million by 2030 from $2588.6 million in 2019, at a CAGR of 15.87% during the forecast period 2020-2030


BIS Research Report: https://bisresearch.com/industry-report/global-liquid-biopsy-market.html  


This growth has been primarily attributed to the rising number of cancer cases coupled up with the growing awareness pertaining to non-invasive detection approaches, the increasing adoption of inorganic growth strategies by key players in the market, and the increasing research funding from the leading organizations such as the U.S. National Institute of Health, globally.


The market is expected to grow at a significant growth rate due to opportunities such as the introduction of informatics and technological innovations for a large customer base and increasing adoption of cancer and other diseases testing services.


Request for Sample: https://bisresearch.com/requestsample?id=982&type=download   


However, there are significant challenges that are restraining the market growth. These challenges include false negatives and positives, limited and ambiguous reimbursement scenario, expected implementation of Patient Protection and Affordable Care (PPACA) Act (for research used kits and consumables), and existing diagnostic confidence of medical community on liquid biopsy procedures. Despite the substantial investments made by the conglomerate companies of the healthcare industry, the clinical application of liquid biopsy is predominantly limited to treatment monitoring, however adoption is expected to increase owing to the recent approval of GUARDANT360. Several factors such as low confidence of the physicians, uncertainty pertaining to approval scenario, and a lack of favorable reimbursement policies are the leading factors hampering the growth of the global liquid biopsy market.


  Key Questions Answered in the Report
 What are the major market drivers, challenges, and opportunities in the global liquid biopsy market?

  What are the key development strategies which are implemented by the major players to sustain in the competitive market?

 Which is the dominant product type developed by the leading and emerging players for liquid biopsy?

What are the key technologies that have been used by leading players in the global liquid biopsy market for the development of diagnostic and research solutions for cancer?

How each segment of the market is expected to grow during the forecast period from 2020 to 2030?


Labels

Labels:

Comments

Post a Comment

Popular posts from this blog

Pharmacogenomics Services Market Dynamics, Competitive Landscape & Forecast to 2031

  BIS healthcare experts have found the pharmacogenomics services industry to be one of the most rapidly evolving and dynamic markets. The global  pharmacogenomics services market  is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031. The market is driven by certain factors, including increasing prevalence of infectious diseases and various types of cancer, increasing adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development. Currently, the pharmacogenomics services industry is witnessing an upsurge due to the increasing prevalence of infectious diseases and various types of cancer, increase in adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogen...
Post a Comment
Read more

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...
Post a Comment
Read more